Showing 1 – 20 of 145
Relevance | Newest | Oldest |
  • JAMA November 8, 2016

    Figure 3: Subgroup Analysis of Breast Cancer Recurrence–Free Survival (BCRFS) Events

    The size of each box is proportional to the size of the respective subgroup. ER indicates estrogen receptor; HER2, human epidermal growth factor receptor 2 gene; and PR, progesterone receptor.
  • JAMA May 21, 2014

    Figure 1: Survival of Patients

    ALK indicates anaplastic lymphoma kinase gene; EGFR(s), epidermal growth factor receptor gene (sensitizing); EGFR(o), epidermal growth factor receptor gene (other); KRAS, Kirsten rat sarcoma; NA, not applicable.A, The median survival 2.65 years (95% CI, 2.35-2.93). B, Median survival (95% CI): EGFR(s), 3.97 years (3.21-4.64); EGFR(o), 2.70 years (1.42-NA); ALK, 4.25 years (2.92-NA); KRAS, 2.41 years (1.87-3.21); doubletons (oncogenic drivers in 2 genes), 2.03 years (1.39-2.84). Vertical tick marks are censoring events.
  • JAMA May 21, 2014

    Figure 2: Survival Comparisons

    ALK indicates anaplastic lymphoma kinase gene; EGFR(s), epidermal growth factor receptor gene (sensitizing); EGFR(o), epidermal growth factor receptor gene (other); KRAS, Kirsten rat sarcoma; NA, not applicable.A, Median survival (95% CI): oncogenic driver + no targeted therapy, 2.38 (1.81-2.93); oncogenic driver + targeted therapy, 3.49 (3.02-4.33); no oncogenic driver, 2.08 (1.84-2.46). B, Survival by oncogenic driver detected for patients with the 5 most frequent oncogenic drivers and targeted treatment. Median survival (95% CI): EGFR(s), 3.78 (2.77-NA); EGFR(o), 2.70 (1.42-NA); ALK, NA (2.80-NA); KRAS, 4.85 (1.30-NA); doubletons (oncogenic drivers in 2 genes), 2.69 (1.94-NA). Vertical tick marks are censoring events.
  • Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

    Abstract Full Text
    free access is expired quiz has multimedia
    JAMA. 2014; 311(19):1998-2006. doi: 10.1001/jama.2014.3741

    Kris and coauthors determine the frequency of oncogenic drivers in patients with lung adenocarcinomas and use the data to select treatments targeting the identified driver(s) and measure survival among 1007 US patients with metastatic lung adenocarcinomas.

  • Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non–Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor: A Meta-analysis

    Abstract Full Text
    free access
    JAMA. 2014; 311(14):1430-1437. doi: 10.1001/jama.2014.3314

    J.-K. Lee and coauthors performed a systematic review and meta-analysis to determine the association between survival and first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors vs chemotherapy among patients with advanced non–small cell lung cancer with wild-type EGFR.

  • JAMA April 9, 2014

    Figure 1: Trial Selection Process

    EGFR indicates epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.
  • JAMA April 9, 2014

    Figure 4: Subgroup Analyses for Progression-Free Survival According to the Line of Treatment (First vs Second or Later), EGFR TKI Agents, Ethnicity, and EGFR Mutation Analysis Methods for Patients With WT EGFR

    The treatment effects were calculated with a random-effects model. EGFR indicates epidermal growth factor receptor; HR, hazard ratio; TKI, tyrosine kinase inhibitor.
  • JAMA April 9, 2014

    Figure 2: Progression-Free Survival From the 10 Randomized Controlled Trials Comparing EGFR TKI With Chemotherapy

    The size of the data markers (squares) corresponds to the weight of the study in the meta-analysis. The treatment effects were calculated with a random-effects model. (Numbers of events when reported are shown in eTable 1 in the Supplement.) EGFR indicates epidermal growth factor receptor; HR, hazard ratio; TKI, tyrosine kinase inhibitor.
  • Rates of Treated and Untreated Kidney Failure in Older vs Younger Adults

    Abstract Full Text
    free access
    JAMA. 2012; 307(23):2507-2515. doi: 10.1001/jama.2012.6455
    Among a population-based cohort of 1816824 adults in Alberta, Canada, Hemmelgarn and coauthors evaluate the extent to which age is associated with the likelihood of treatment of kidney failure.
  • JAMA February 15, 2012

    Figure 1: Randomization and Treatment

    Twenty-four− and 48-week data (postbaseline visits) represent the number of participants included in the primary analysis using a mixed-effects repeated-measures model. iPTH indicates intact parathyroid hormone; eGFR, estimated glomerular filtration rate; RAAS, renin-angiotensin-aldosterone system.
  • JAMA February 10, 2010

    Figure 2: Comparisons of Mean Probability (or Level) of Oncogenic Pathway Activation Between Age Groups

    Error bars indicate 95% confidence intervals. WH indicates wound healing; TNF, tumor necrosis factor; STAT3, signal transducer and activator of transcription 3; CIN, chromosomal instability; EPI, epigenetic stem cell; IGS, invasiveness; EGFR, epidermal growth factor receptor. By unpaired, 1-tailed t tests, P<.001 for β-catenin and IGS; P<.01 for Src.
  • JAMA February 10, 2010

    Figure 6: Comparisons of Mean Probability (or Level) of Oncogenic Pathway Activation by Sex

    Error bars indicate 95% confidence intervals. WH indicates wound healing; TNF, tumor necrosis factor; STAT3, signal transducer and activator of transcription 3; CIN, chromosomal instability; EPI, epigenetic stem cell; IGS, invasiveness; EGFR, epidermal growth factor receptor. By unpaired, 1-tailed t tests, P<.05 for E2F1, EPI, and Myc; P<.01 for CIN, IGS, and WH.
  • Relation Between Kidney Function, Proteinuria, and Adverse Outcomes

    Abstract Full Text
    free access
    JAMA. 2010; 303(5):423-429. doi: 10.1001/jama.2010.39
  • JAMA May 6, 2009

    Figure: Dual-Binding Antibody

    Researchers have found a variant of trastuzumab that can bind both human epidermal growth factor receptor 2 (HER2) and vascular endothelial growth factor (VEGF).
  • JAMA May 6, 2009

    Figure 3: Univariate and Sex- and Age-Adjusted Proportional Hazards Analysis of Association With the First Venous Thromboembolism

    eGFR indicates estimated glomerular filtration rate; MI, myocardial infarction; UAE, urinary albumin excretion; VTE, venous thromboembolism. To convert values for cholesterol, HDL, and LDL to mmol/L, multiply by 0.0259; to convert values for triglycerides to mmol/L, multiply by 0.0113; to convert CRP to nmol/L multiply by 9.524; to convert PAI-1 to pmol/L, multiply by 19.231. aSex- and age-adjusted hazard ratios (HRs) with corresponding 95% confidence intervals (95% CIs). Sex was adjusted for age only and age for sex only. Use of oral contraceptives was also adjusted for age only. bBody mass index (BMI [calculated as weight in kilograms divided by height in meters squared]), metabolic syndrome, cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglycerides were classified according to the Adult Treatment Panel III of the National Cholesterol Education Program.cC-reactive protein (CRP) was classified according to the Centers for Disease Control and Prevention and the American Heart Association.dSince normal ranges of tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) in the general population are unknown, we dichotomized these variables using their medians as cutoffs.
  • JAMA July 4, 2007

    Figure: Epidermal Growth Factor Receptor Activation, Processing, and Signaling

    ATP indicates adenosine triphosphate; Cbl, a ubiquitin E3 ligase; IGF, insulinlike growth factor; JAK, Janus kinase; MAPK, mitogen-activated protein kinase; P, phosphate; PDGF, platelet-derived growth factor; PI3K, phosphatidylinositol-3-kinase; PKC, protein kinase C; PLC-γ, phospholipase Cγ; STAT, signal transducers and activators of transcription; TK, tyrosine kinase; and Ub, ubiquitin.
  • Therapies Directed Against Epidermal Growth Factor Receptor in Aerodigestive Carcinomas

    Abstract Full Text
    free access is expired quiz
    JAMA. 2007; 298(1):70-82. doi: 10.1001/jama.298.1.70
  • JAMA June 7, 2006

    Figure 1: Immunohistochemical Identification of Breast Tumor Intrinsic Subtypes

    The 115 patient/tumor sample dendrogram was taken from the hierarchical clustering analysis of the breast intrinsic gene list. Tissue samples in gray indicate unknown subtype. The gene expression data for estrogen receptor (ER), human epidermal growth factor receptor-2 (HER2), CK5 (cytokeratin), and HER1 are shown with red squares representing the highest average expression, black representing average gene expression, and green representing the lowest below average expression. Gray indicates gene expression data not available. Note that PR (progesterone receptor) was not included in this gene expression analysis because it was not present on these early generation microarrays. Below the gene expression data are the revised immunohistochemical (IHC) classification schema used in this study. PR was added to the IHC profile since it is an ER-regulated gene expressed in most ER+ tumors.
  • JAMA April 27, 2005

    Figure: Will Lung Cancer Targeting Hit Its Mark?

    Treatments for lung cancer have expanded recently, particularly targeted therapies for patients with non[[ndash]]small-cell lung cancer.
  • JAMA April 27, 2005

    Figure: Will Lung Cancer Targeting Hit Its Mark?

    A number of EGFR inhibitors are currently available or in clinical trials, both as single-agent therapies and in combination with conventional treatments, for lung and other cancers.